$11.13 B
Share price
Change (1 day)
Change (1 year)
Insulet Corporation is an American company that develops and sells medical devices used for the administration of insulin.

P/E ratio for Insulet (PODD)

P/E ratio as of October 2023 (TTM): 182

According to Insulet's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 182.067. At the end of 2021 the company had a P/E ratio of > 1000.

P/E ratio history for Insulet from 2007 to 2022

PE ratio at the end of each year

Year P/E ratio Change
2021> 1000-50.22%
2020> 1000144.34%
2018> 1000-981.33%

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
31.6-82.67%๐Ÿ‡บ๐Ÿ‡ธ USA
29.8-83.64%๐Ÿ‡บ๐Ÿ‡ธ USA
28.9-84.11%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
76.7-57.88%๐Ÿ‡บ๐Ÿ‡ธ USA
-5.99-103.29%๐Ÿ‡บ๐Ÿ‡ธ USA
-58.7-132.24%๐Ÿ‡บ๐Ÿ‡ธ USA
103-43.62%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.